Compare Viatris Inc (VTRS) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Energy Select Sector SPDR Fund — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Energy Select Sector SPDR Fund trades at $58.54. The key difference: Viatris Inc pays a 2.83% dividend while Energy Select Sector SPDR Fund pays none, and Viatris Inc is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| VTRS | XLE | |
|---|---|---|
Market Cap | $19.79B | — |
Sector | Health | — |
52-Week High | $17.39 | $62.57 |
52-Week Low | $8.74 | $42.12 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
XLE trades at $57.96, up 0.49% today, with a bullish technical signal supported by moving averages but showing overbought RSI readings. The ETF maintains a low 0.08% expense ratio and focuses on S&P 500 energy giants. Recent news highlights XLE's competitive advantages in liquidity and cost structure compared to energy infrastructure ETFs.
Outlook remains positive given elevated oil prices and strong sector earnings growth expectations, though overbought conditions and geopolitical risks warrant caution. The ETF's concentration in major energy companies provides stable exposure to traditional energy sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
